Chicago, IL – July 19, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. AAPL, UnitedHealth Group Inc. UNH, Equinor ASA EQNR, GSK plc GSK and Eaton Corp. plc ETN.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Apple, UnitedHealth, Equinor & Others
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., UnitedHealth Group Inc. and Equinor ASA. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Apple shares have gained +3.6% over the past year against the Zacks Tech sector's -24.7% decline and the S&P 500 index's -9.9% decline. The company is benefiting from continued momentum in the Services and robust performance from iPhone, Mac, Wearables and an expanding App Store ecosystem.
Nevertheless, the availability of new Mac Studio and new iPad Air is expected to drive top-line growth. Apple TV+ is gaining recognition due to award-winning shows. This bodes well for the Services segment. Services revenue growth is expected to be in strong double digits for the June quarter.
However, Apple did not provide revenue guidance for the third quarter of fiscal 2022. Apple expects COVID-induced supply chain disruptions and industry-wide silicon shortages to hurt the top line along with unfavorable forex condition is also expected to hurt its revenues. The absence of Russian revenues will also hurt the top line.
(You can read the full research report on Apple here >>>)
UnitedHealth shares have outperformed the Zacks Medical - HMOs industry over the past year (+31.2% vs. +26.6%). The zacks analyst believes that the company's top line has been growing and the momentum should continue in the years ahead on the back of a strong market position and an attractive core business that continues to be driven by new deals, renewed agreements and expansion of service offerings.
For this year, the company expects revenues in the range of $317-$320 billion. Its solid health services segment provides diversification benefits. The firm's government business remains well-poised for growth. A sturdy balance sheet enables investments and prudent capital deployment through share buybacks and dividends.
However, softness in commercial business due to COVID-induced volatilities persists. Also, the rising operating costs are hurting UnitedHealth's bottom line. As such, the stock warrants a cautious stance.
(You can read the full research report on UnitedHealth here >>>)
Equinor shares have outperformed the Zacks Oil and Gas - Refining and Marketing industry over the past year (+75.4% vs. +46.2%). The company is one of the premier integrated energy companies, with operations spreading across 30 countries. In 2021, the company completed 21 exploration wells, with 8 commercial discoveries.
Equinor announced significant oil discoveries at the Johan Castberg field in the Barents Sea, which will further increase its profitability in the field. To combat climate change, the company is actively investing in renewable energy projects, comprising power generation from solar and wind energy. For 2022, Equinor announced the increase of the share buy-back program of up to $5 billion.
However, the company's significant exposure to debt can affect its financial flexibility. Also, it is not being able to capture the potential profit growth from commodity prices that have reached record highs. As such, the stock warrants a cautious stance.
(You can read the full research report on Equinor here >>>)
Other noteworthy reports we are featuring today include GSK plc (GSK) and Eaton Corp. plc (ETN).
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
